首页>投融资
南京传奇生物
增发
传奇生物是一家肿瘤细胞免疫疗法研发商,研发了CD38和BCMA靶点治疗多发性骨髓瘤的CAR-T疗法,利用自身免疫细胞,经体外基因改造后重新注射回病人体内,并利用这种强化过的免疫细胞精准靶向,杀死肿瘤细胞,主要用于治疗血癌和淋巴癌。
基本信息
-
公司全称南京传奇生物科技有限公司
-
类型肿瘤细胞免疫疗法研发商
-
产业领域药品研发/制造、生物药
-
公司人数500人以上
-
地址南京市江宁区龙眠大道568号南京生命科技小镇6号楼3、4层(江宁高新园)
-
联系电话025-58897288
-
邮箱xiufa.gu@legendbiotech.com
-
成立时间2014-11-16
投融资
-
2023-05-03定向增发1270万美元高瓴资本
-
2023-05-03增发1270万美元高瓴资本
-
2021-05-21增发5亿美元高瓴资本
-
2021-05-16IPO后其他轮次5亿美元高瓴资本
-
2020-06-05IPO4.24亿美元未透露
-
2020-06-05上市4.24亿美元未透露
-
2020-03-31战略融资1.5亿美元礼来亚洲基金维梧资本Hudson Bay CapitalJohnson & Johnson InnovationRA Capital
-
2020-03-31股权融资1.5亿美元Johnson & Johnson Innovation礼来亚洲基金Hudson Bay CapitalRA Capital维梧资本
- 加载更多
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司,开发工程化单体 IgA 中性粒细胞接合器,以释放中性粒细胞对癌症的肿瘤杀伤能力,以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心(荷兰乌得勒支)进行的开创性工作,并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem